Skip to main content

CohBar — Company Overview, News & Financial Data

CohBar logo
CohBar
CohBar primary media
Company profile

CohBar

About

CohBar (NASDAQ:CWBR) is a biotechnology company focused on the research and development of mitochondria-based therapeutics (MBTs), an innovative class of drugs intended to treat diseases associated with aging and metabolic dysfunction. The company's pipeline includes projects aimed at tackling a wide range of conditions, including obesity, type 2 diabetes, cancer, and cardiovascular diseases, by leveraging the therapeutic potential of mitochondrial-derived peptides (MDPs). With a mission to extend healthy lifespan and improve the quality of life, CohBar's ongoing research and development activities underscore its commitment to pioneering the exploration of mitochondria's role in health and disease.

Snapshot

2007Year founded
6Employees
Menlo Park, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Edison, US

Products and/or services of CohBar

  • Mitochondria based therapeutics for age-associated diseases, focusing on metabolic disorders.
  • Development of peptides derived from mitochondria for potential treatment of cancer.
  • Research into mitochondrial-derived peptides (MDPs) for cardiovascular diseases.
  • Exploring therapeutic potentials in neurodegenerative diseases with mitochondrial peptides.

CohBar executive team

  • Dr. Pinchas Cohen Dean, M.D., Ph.D.Founder & Member of Scientific Advisory Board
  • Dr. Nir Yacov Barzilai M.D.Founder & Member of Scientific Advisory Board
  • Dr. John M. Amatruda M.D., Ph.D.Co-Founder
  • Ms. Jordyn TaraziDirector of Investor Relations

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift